xanderla implantaat süstlis
teva b.v. - gosereliin - implantaat süstlis - 10,8mg 3tk; 10,8mg 2tk
reseligo implantaat süstlis
zentiva k.s. - gosereliin - implantaat süstlis - 10,8mg 1tk; 10,8mg 3tk
xanderla implantaat süstlis
teva b.v. - gosereliin - implantaat süstlis - 3,6mg 2tk; 3,6mg 3tk
nexplanon implantaat
organon n.v. - etonogestreel - implantaat - 68mg 5tk; 68mg 1tk
reseligo implantaat süstlis
zentiva k.s. - gosereliin - implantaat süstlis - 3,6mg 3tk
esperal impl.tabl. 100mg n10 implantaat
sanofi winthrop - disulfiraam - implantaat - 100mg 10tk
disulfiram implantaat
warsaw pharmaceutical works polfa s.a. - disulfiraam - implantaat - 100mg 10tk
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.